The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung disease has no known cause. The therapy will be marketed under the brand name Jascayd. According to a…
Read more
In just over a month, one of the largest gatherings of pulmonary fibrosis (PF) patients, caregivers, and health professionals will take place in Chicago, at the Pulmonary Fibrosis Foundation (PFF) Summit 2025. My idiopathic pulmonary fibrosis (IPF) diagnosis in January 2017 thrust my wife, Susan, and me…
Treatment with the experimental therapy nerandomilast appears to reduce the risk of death in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), according to a new analysis of clinical trial data presented by the therapy’s developer, Boehringer Ingelheim. “The new pooled data zoom in on…
Becoming educated and informed about PF is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your PF journey.
There is no cure for PF yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
